Rare eye disease biotech Applied Genetic Technologies files for a $70 million IPO

Shutterstock photo

Applied Genetic Technologies, a clinical-stage biotech developing treatments for orphan eye diseases, filed on Friday with the SEC to raise up to $70 million in an initial public offering. The Alachua, FL-based company, which was founded in 1999 and booked $1 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol AGTC. Barclays and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?